Nutrition Status, BMD, and SSRIs

BMD Clinical Trial

Official title:

Nutrition Status, Bone Mass Density, and Selective Serotonin Reuptake Inhibitors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03383861
• Other study ID #: 174318
• Status: Terminated
• Start date: January 2005
• Est. completion date: December 2014

Study information

• Verified date: January 2024
• Source: University of New Mexico
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The association between selective serotonin reuptake inhibitor (SSRI) use and bone mass density (BMD) has been debated. Some have suggested features of depression, which SSRIs are prescribed to treat, may be a cause of decreased BMD, such as poor overall food intake at the time of SSRI use. Our study seeks to determine whether SSRI use in adults is associated with lower than average BMD, and if there is an association between low micronutrient intake, SSRI use, and a low BMD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13027
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Included adult NHANES participants are those who participated in the Dual-Energy X-ray Absorptiometry (DXA) femur-neck BMD test and responded in full to the demographic, pharmaceutical, and dietary surveys.

Exclusion Criteria:

• Pregnancy, incomplete survey responses, incomplete DXA results

Related Conditions & MeSH terms

• BMD

Intervention

Diagnostic Test:
• Dual-Energy X-ray Absorptiometry (DXA)
BMD t-score derived from DXA scan

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of New Mexico

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BMD t-score		NHANES DXA measurement taken 2005-2014